Global Neoantigen Cancer Vaccine Market Size, Status and Forecast 2020-2026

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Personalized Vaccine
  • 1.4.3 Off-the-shelf Neovaccines
• 1.5 Market by Application
  • 1.5.1 Global Neoantigen Cancer Vaccine Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 Neoantigen Cancer Vaccine Market Perspective (2015-2026)
• 2.2 Neoantigen Cancer Vaccine Growth Trends by Regions
  • 2.2.1 Neoantigen Cancer Vaccine Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neoantigen Cancer Vaccine Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Neoantigen Cancer Vaccine Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Neoantigen Cancer Vaccine Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Neoantigen Cancer Vaccine Players by Market Size
  • 3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2015-2020)
  • 3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Neoantigen Cancer Vaccine Market Concentration Ratio
  • 3.2.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2019
• 3.3 Neoantigen Cancer Vaccine Key Players Head office and Area Served
• 3.4 Key Players Neoantigen Cancer Vaccine Product Solution and Service
• 3.5 Date of Enter into Neoantigen Cancer Vaccine Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2015-2020)
• 4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2021-2026)

5 Neoantigen Cancer Vaccine Breakdown Data by Application (2015-2026)

• 5.1 Global Neoantigen Cancer Vaccine Market Size by Application (2015-2020)
• 5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neoantigen Cancer Vaccine Market Size (2015-2020)
• 6.2 Neoantigen Cancer Vaccine Key Players in North America (2019-2020)
• 6.3 North America Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 6.4 North America Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Neoantigen Cancer Vaccine Market Size (2015-2020)
• 7.2 Neoantigen Cancer Vaccine Key Players in Europe (2019-2020)
• 7.3 Europe Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 7.4 Europe Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

8 China

• 8.1 China Neoantigen Cancer Vaccine Market Size (2015-2020)
• 8.2 Neoantigen Cancer Vaccine Key Players in China (2019-2020)
• 8.3 China Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 8.4 China Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Neoantigen Cancer Vaccine Market Size (2015-2020)
• 9.2 Neoantigen Cancer Vaccine Key Players in Japan (2019-2020)
• 9.3 Japan Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 9.4 Japan Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Neoantigen Cancer Vaccine Market Size (2015-2020)
• 10.2 Neoantigen Cancer Vaccine Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 10.4 Southeast Asia Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

11 India

• 11.1 India Neoantigen Cancer Vaccine Market Size (2015-2020)
• 11.2 Neoantigen Cancer Vaccine Key Players in India (2019-2020)
• 11.3 India Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 11.4 India Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Neoantigen Cancer Vaccine Market Size (2015-2020)
• 12.2 Neoantigen Cancer Vaccine Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
• 12.4 Central & South America Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview and Its Total Revenue
  • 13.1.3 Roche Neoantigen Cancer Vaccine Introduction
  • 13.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Medimmune
  • 13.2.1 Medimmune Company Details
  • 13.2.2 Medimmune Business Overview and Its Total Revenue
  • 13.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
  • 13.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.2.5 Medimmune Recent Development
• 13.3 Merck
  • 13.3.1 Merck Company Details
  • 13.3.2 Merck Business Overview and Its Total Revenue
  • 13.3.3 Merck Neoantigen Cancer Vaccine Introduction
  • 13.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.3.5 Merck Recent Development
• 13.4 Advaxis
  • 13.4.1 Advaxis Company Details
  • 13.4.2 Advaxis Business Overview and Its Total Revenue
  • 13.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
  • 13.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.4.5 Advaxis Recent Development
• 13.5 Agenus
  • 13.5.1 Agenus Company Details
  • 13.5.2 Agenus Business Overview and Its Total Revenue
  • 13.5.3 Agenus Neoantigen Cancer Vaccine Introduction
  • 13.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.5.5 Agenus Recent Development
• 13.6 Genocea
  • 13.6.1 Genocea Company Details
  • 13.6.2 Genocea Business Overview and Its Total Revenue
  • 13.6.3 Genocea Neoantigen Cancer Vaccine Introduction
  • 13.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.6.5 Genocea Recent Development
• 13.7 Gritstone Oncology
  • 13.7.1 Gritstone Oncology Company Details
  • 13.7.2 Gritstone Oncology Business Overview and Its Total Revenue
  • 13.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
  • 13.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.7.5 Gritstone Oncology Recent Development
• 13.8 Neon Therapeutics
  • 13.8.1 Neon Therapeutics Company Details
  • 13.8.2 Neon Therapeutics Business Overview and Its Total Revenue
  • 13.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
  • 13.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.8.5 Neon Therapeutics Recent Development
• 13.9 Nouscom
  • 13.9.1 Nouscom Company Details
  • 13.9.2 Nouscom Business Overview and Its Total Revenue
  • 13.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
  • 13.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.9.5 Nouscom Recent Development
• 13.10 OSE Immunotherapeutics
  • 13.10.1 OSE Immunotherapeutics Company Details
  • 13.10.2 OSE Immunotherapeutics Business Overview and Its Total Revenue
  • 13.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
  • 13.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 13.10.5 OSE Immunotherapeutics Recent Development
• 13.11 Medigene
  • 10.11.1 Medigene Company Details
  • 10.11.2 Medigene Business Overview and Its Total Revenue
  • 10.11.3 Medigene Neoantigen Cancer Vaccine Introduction
  • 10.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 10.11.5 Medigene Recent Development
• 13.12 Vaccibody
  • 10.12.1 Vaccibody Company Details
  • 10.12.2 Vaccibody Business Overview and Its Total Revenue
  • 10.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
  • 10.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 10.12.5 Vaccibody Recent Development
• 13.13 Brightpath Biotherapeutics
  • 10.13.1 Brightpath Biotherapeutics Company Details
  • 10.13.2 Brightpath Biotherapeutics Business Overview and Its Total Revenue
  • 10.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
  • 10.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 10.13.5 Brightpath Biotherapeutics Recent Development
• 13.14 Geneos Therapeutics
  • 10.14.1 Geneos Therapeutics Company Details
  • 10.14.2 Geneos Therapeutics Business Overview and Its Total Revenue
  • 10.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
  • 10.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
  • 10.14.5 Geneos Therapeutics Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer